Eczacıbaşı İlaç Pazarlama

What Eczacıbaşı İlaç Pazarlama does

Eczacıbaşı İlaç Pazarlama A.Ş. is a Turkish pharmaceutical marketing and distribution company headquartered in Istanbul, operating as a subsidiary of the Eczacıbaşı Holding conglomerate. Incorporated in 1989 — with roots in the Eczacıbaşı Group's pharmaceutical activities dating to 1942 — the company markets, promotes, sells, and distributes imported and contract-manufactured pharmaceuticals through two business units: an RX Group handling prescription drugs across oncology, hematology, dermatology, gastroenterology, neurology, musculoskeletal, genitourinary, endocrinology, and infectious diseases; and a Consumer Health unit covering over-the-counter medications (notably Vicks) and dietary supplements (Dynavit, Selfit, İmutor, Proxeed Plus, Medigard).

The company operates a nationwide field sales organization of more than 300 representatives and over 30 district managers covering all 59 provinces of Turkey, with daily visit activity processed and monitored through a proprietary sales force automation system. The field force regularly visits 25,000+ doctors, 2,500+ dentists, and 8,000+ pharmacies. Its international supply base is assembled through licensing and distribution partnerships with firms including Novartis Oncology, Sanofi, Galderma, Almirall, Chugai, BioGaia, Tillotts Pharma, Synthon, Procter & Gamble, Juvisé Pharmaceuticals, Aspen, and others spanning 11 countries. Proprietary consumer brands include Dynavit (vitamins, minerals, supplements), Selfit, and İmutor, alongside licensed brands such as Vicks, Proxeed Plus, and Medigard.

After divesting its pharmaceutical manufacturing assets to Zentiva N.V. in 2007-2009, the company repositioned as a marketing and distribution-focused business. It employs 251-500 staff and has not publicly disclosed revenue. Go-to-market combines extensive physician/dentist detailing with pharmacy distribution and consumer-facing channels (social media, corporate magazine, sports sponsorship via the Eczacıbaşı Dynavit Women's Volleyball Team). Capital Markets Board (SPK) approvals for debt instrument issuance limits were granted in October 2023 and December 2025, indicating access to public debt capital markets. The CEO is Atalay Gümrah and General Manager (per security policy record) is Başbuğ Öke.

Name

Eczacıbaşı İlaç Pazarlama

Legal name

Eczacıbaşı İlaç Pazarlama A.Ş.

Website

https://eczacibasiilac.com.tr

Company type

Private

Founded year

1989

Operating status

Operating

Headcount range

251–500 employees

Short description

Eczacıbaşı İlaç Pazarlama is a Turkish pharmaceutical marketing and distribution company selling imported prescription drugs, OTC products, and own-branded dietary supplements through a 300-representative nationwide field force covering 25,000+ doctors and 8,000+ pharmacies.

Ownership category

akta.pro rank

Product category

Pharmaceutical Marketing and Distribution

NAICS

Health and Personal Care Retailers (456)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Pharmacy Front-End & Sundries Distribution (Health & Wellness, Personal Care, Convenience) (CRAOAHAG)

akta.pro secondary industries

Health, Wellness & Pharmacy Marketplaces (CRAFABAF), Health & Pharmacy Omnichannel (CRAFAEAK), Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Pharmaceutical marketing
• Prescription drug distribution
• Over-the-counter medicines
• Food supplements
• Field sales force

Headquarters

HQ city

Istanbul

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Operations, Supply Chain, Technology or R&D

Revenue model

1. Prescription Pharmaceuticals (RX): Marketing, promotion, sales and distribution of imported and contract-manufactured prescription pharmaceuticals through a nationwide field sales force covering doctors, dentists and pharmacies.
2. Consumer Health / OTC and Supplements: Consumer health products including Dynavit vitamin/mineral/food supplement brand, Selfit supplement brand, Imutor supplements, Vicks OTC brands, and other personal care products distributed through pharmacy channels.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Eczacıbaşı İlaç Pazarlama is the pharmaceutical marketing, promotion, sales and distribution arm of the Eczacıbaşı Group in Turkey. It operates two business units — RX Group, which sells prescription pharmaceuticals across oncology, gastroenterology, dermatology, urology, neurology, and infectious diseases, and Consumer Health, which markets over-the-counter remedies and the owned Dynavit, Selfit and İmutor food supplement brands as well as licensed brands such as Vicks. The company uses a nationwide field sales organization of more than 300 representatives and 30+ district managers to reach over 25,000 doctors, 2,500 dentists and 8,000 pharmacies across all 59 provinces of Turkey.

Product overview

Eczacıbaşı İlaç Pazarlama operates two main business units: RX Group (prescription pharmaceuticals) and Consumer Health (over-the-counter medicines and food supplements). The company markets, promotes, sells, and distributes imported and contract-manufactured pharmaceuticals through licensed partnerships with international companies including Almirall, BioGaia, Chugai, Galderma, Procter & Gamble, Sanofi, and Tillotts Pharma. Its consumer health portfolio includes owned brands Dynavit (vitamins, minerals, and food supplements), Selfit, and İmutor, along with licensed brands Vicks, Proxeed Plus, and Medigard. The prescription pharmaceutical portfolio spans oncology, gastroenterology, dermatology, urology, central nervous system, infectious diseases, musculoskeletal disorders, hematology, and endocrinology treatments. The company maintains a nationwide sales network covering 59 cities, visiting over 25,000 doctors, 2,500 dentists, and 8,000 pharmacies regularly.

Differentiator

Problem solved

Functional benefit

Brands

• Dynavit: Vitamin, mineral and food supplement brand launched in 2021
• Selfit
• İmutor
• Proxeed Plus

Products and services

• Dynavit Vitamin, mineral and food supplement brand offering multivitamins (Multi Daily), Vitamin D3 sprays/drops, B12 supplements, collagen products (Diamond Collagen, Collagen Quatro), Omega 3, Coenzyme Q10, probiotics with propolis and beta glucan, magnesium supplements (Mag Complex, Mag Focus), children's supplements (Ferrokid, Arjikid Multi, Balık Yağı, Fosfokid, Immukid Gummies, Lizinkid, Sambukid-C), biotin, selenium, Korean Ginseng Complex, and formulations such as NMN Collagen, Reducose and Sulforafan Kolin Kompleks, targeted at consumers seeking nutritional supplementation through Turkish pharmacy channels.
• Selfit Food supplement sub-brand featuring Omega 3, Magnesium Citrate with Vitamin D, Korean Ginseng Complex, Collagen with Hyaluronic Acid, Vitamin B12, 5-HTP, Biotin, Bromelain, Chromium Picolinate, L-Carnitine with Guarana, and Vitamin C products, positioned as a consumer supplement range distributed through Turkish pharmacy channels.
• İmutor Beta Glukan-based immune support supplement brand with products including Beta Glukan capsules, Kompleks capsules and Kompleks Sıvı (liquid form) containing Echinacea, Propolis, Vitamin C and Zinc, targeted at consumers seeking immune system support through Turkish pharmacy channels.
• Vicks Licensed over-the-counter cold and flu relief brand distributed in Turkey through Eczacıbaşı İlaç Pazarlama, including Vicks First Defence nasal spray, Vicks Inhaler, Vicks Vapodry syrup and Vicks Vaporub volatile ointment for consumer self-medication through pharmacy retail channels.
• Proxeed Plus Nutritional supplement in sachet form containing a carnitine combination with vitamins and minerals, positioned for consumers seeking nutritional support distributed through Turkish pharmacy channels.
• Medigard Coenzyme Q10 and multivitamin/mineral supplement brand distributed through Turkish pharmacy channels.
• Arimidex 1 mg film-coated tablet containing Anastrozole, a prescription pharmaceutical for oncology (breast cancer) treatment, distributed through Turkish hospital and pharmacy channels under prescription.
• Asacol Mesalazine-based prescription pharmaceutical available in 500 mg suppositories, 800 mg enteric tablets and 4 g/100 mL rectal suspension, used for gastrointestinal diseases (ulcerative colitis, inflammatory bowel disease) and distributed through Turkish hospital and pharmacy channels.
• Casodex Bicalutamide film-coated tablets in 50 mg and 150 mg doses for prostate cancer (oncology) treatment, distributed through Turkish hospital and pharmacy channels under prescription.
• Emselex Darifenacin hydrobromide prolonged-release tablets in 7.5 mg and 15 mg doses for overactive bladder symptoms (genitourinary), distributed through Turkish hospital and pharmacy channels under prescription.
• İmovane 7.5 mg film-coated tablet containing Zopiclone for the treatment of sleep disorders, distributed through Turkish hospital and pharmacy channels under prescription (central nervous system therapy).
• Sef Cefalexin monohydrate antibiotic available in 1000 mg and 500 mg film-coated tablets and oral suspension forms (250 mg/5 mL and 500 mg/5 mL) for infectious disease treatment, distributed through Turkish hospital and pharmacy channels under prescription.
• Suprax Cefixime antibiotic in 400 mg film-coated tablets, 400 mg dispersible tablets (DT) and 100 mg/5 mL pediatric oral suspension for infectious disease treatment, distributed through Turkish hospital and pharmacy channels under prescription.
• Differin 0.1% adapalene gel for acne treatment, distributed through Turkish hospital and pharmacy channels under prescription (dermatology).

Quantifiable outcome

• Reached over 25,000 doctors, 2,500 dentists, and 8,000 pharmacies nationwide
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

18 partnerships are on record, tiered core and minor.

• Novartis Onkoloji TürkiyecoreStrategic or Co-development Partner · 1 August 2019Partnership established August 1, 2019 for the sale, promotion, and distribution of three cancer treatment drugs (Acromegaly, NET, GIST, CML, and Lung Cancer) whose licenses are owned by Novartis. Eczacıbaşı was granted exclusive rights to sell, promote, and distribute these products in Turkey.
• P&G (Procter & Gamble)coreChannel Partner/ Reseller/ Distributor · 1 January 2014Partnership established in 2014 within P&G's healthcare group growth target. P&G aims to offer its products to more pharmacy channel consumers through this collaboration, expanding access to pharmacy retail networks in Turkey.
• Abdi İbrahimminorStrategic or Co-development PartnerDomestic Turkish pharmaceutical partnership; Abdi İbrahim is one of Turkey's leading pharmaceutical companies.
• AlfasigmaminorStrategic or Co-development PartnerItalian pharmaceutical company based in Bologna, Italy; partnership for licensed pharmaceutical products in Turkey.
• AlmirallcoreStrategic or Co-development PartnerSpanish pharmaceutical company based in Barcelona, Spain; provides licensed innovative and generic products for the Turkish market.
• AspenminorStrategic or Co-development PartnerSouth African pharmaceutical company based in Durban; licensed product distribution partnership.
• BioGaiacoreStrategic or Co-development PartnerSwedish probiotic company based in Stockholm; provides licensed probiotic products distributed by Eczacıbaşı in Turkey.
• ChugaicoreStrategic or Co-development PartnerJapanese pharmaceutical company based in Tokyo; provides licensed innovative pharmaceutical products for the Turkish market.
• GaldermacoreStrategic or Co-development PartnerSwiss dermatology-focused pharmaceutical company based in Lausanne; licensed dermatology products distributed in Turkey.
• Haver İlaçminorStrategic or Co-development PartnerTurkish pharmaceutical company partnership.
• Juvise PharmaceuticalsminorStrategic or Co-development PartnerFrench pharmaceutical company based in Paris; partnership in psychiatric medicine field established in 2011, beginning with a licensing agreement for an antidepressant used for treatment of mental disorders including anxiety, restlessness, and psychosomatic disorders.
• OtsukaminorStrategic or Co-development PartnerJapanese pharmaceutical company; partnership for licensed pharmaceutical product distribution.
• Pharma MarminorStrategic or Co-development PartnerSpanish pharmaceutical company based in Madrid; licensed oncology and specialty pharmaceutical products.
• RivopharmminorStrategic or Co-development PartnerSwiss pharmaceutical company based in Manno; licensed product distribution partnership.
• SanoficoreStrategic or Co-development PartnerGlobal French pharmaceutical company; provides licensed innovative and generic pharmaceutical products distributed by Eczacıbaşı in Turkey.
• Sesen BiominorStrategic or Co-development PartnerBiotechnology company based in Boston, USA; licensed product distribution partnership for specialty biopharmaceutical products.
• SynthoncoreStrategic or Co-development PartnerDutch pharmaceutical company based in Nijmegen, Netherlands; licensed generic and specialty pharmaceutical products distributed in Turkey.
• Tillotts PharmacoreStrategic or Co-development PartnerSwiss pharmaceutical company based in Rheinfelden; licensed gastroenterology and specialty pharmaceutical products distributed by Eczacıbaşı in Turkey.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Santa Farma: Turkish pharmaceutical manufacturer and distributor with a broad RX portfolio promoted through nationwide HCP and pharmacy coverage. Directly comparable operating model and competitive footprint to Eczacıbaşı İlaç Pazarlama in the Turkish market.
• Ali Raif İlaç: Turkish pharmaceutical manufacturer and distributor with nationwide field coverage across RX and consumer health categories. Comparable in operating model and channel mix to Eczacıbaşı İlaç Pazarlama within the Turkish market.
• Abdi İbrahim: Turkey's largest domestic pharmaceutical company, combining manufacturing with nationwide distribution and field sales across RX, OTC and consumer health. Directly comparable to Eczacıbaşı İlaç Pazarlama in scale, channel coverage, and Turkish-market focus, and even appears in EIP's own partner list.
• Bilim İlaç: Major Turkish pharmaceutical manufacturer and marketer with a broad RX and consumer health portfolio distributed nationwide through pharmacy channels. Competes with Eczacıbaşı İlaç Pazarlama for HCP share of voice and pharmacy shelf space in Turkey.
• Nobel İlaç: Established Turkish pharmaceutical company with manufacturing, marketing, and distribution of branded generics and specialty products through a national pharmacy and HCP channel. Overlaps directly with EIP's RX and OTC/supplement go-to-market in Turkey.

Broad incumbents

• Bayer Turkey: Global life sciences company with a Turkish pharmaceutical and consumer health operation covering RX, OTC and self-care categories. A broad incumbent competing in the same pharmacy channel and HCP promotion environment as Eczacıbaşı İlaç Pazarlama.
• Novartis Turkey: Global pharmaceutical major with its own oncology and specialty operations in Turkey. While Eczacıbaşı İlaç Pazarlama has an exclusive distribution agreement for several Novartis Oncology products, Novartis retains its own broader commercial infrastructure, making it a competing broad incumbent in overlapping therapy areas.
• Sandoz: Global generics leader with a substantial Turkish commercial operation distributing RX and specialty products through pharmacy and hospital channels. A broad incumbent competing in the same categories and channels as Eczacıbaşı İlaç Pazarlama, especially in branded generics and biosimilars.
• Sanofi Turkey: Global pharmaceutical major with direct presence in Turkey across RX, vaccines, and consumer health. Operates as both an EIP partner (for certain products) and a competitor through its own Turkish sales force, making it a broad incumbent across overlapping categories.

Regional players

• Zentiva: European generics company headquartered in Prague that acquired Eczacıbaşı's manufacturing assets in 2007–2009 and now operates a branded generics and OTC business across CEE and Turkey. Historically and operationally linked to Eczacıbaşı İlaç Pazarlama and a regional competitor in the same Turkish categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/eczacibasiilac
• YouTubeyoutube.com/channel/UCSTxUNLUl6-Nu_PxX_BY2yA
• Facebooktr-tr.facebook.com/eczacibasiilacpazarlama
• LinkedInlinkedin.com/company/eczacibasi-ilac-pazarlama
• Instagraminstagram.com/eczacibasiilac

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eczacıbaşı İlaç Pazarlama